Effects of nilotinib on single-dose warfarin pharmacokinetics and pharmacodynamics: a randomized, single-blind, two-period crossover study in healthy subjects.
作者： Ophelia Q.P. Yin , Neil Gallagher , Deirdre Fischer , Lily Zhao , Wei Zhou
DOI: 10.2165/11538700-000000000-00000
关键词:
摘要: Background and Objective: Nilotinib (Tasigna®), a highly selective potent BCR-ABL tyrosine kinase inhibitor, is approved for the treatment of chronic myeloid leukaemia in phase (CML-CP) accelerated (CML-AP) patients resistant or intolerant to prior therapy, including imatinib. has shown competitive inhibition cytochrome P450 enzyme (CYP) 2C9 vitro, but its effect on CYP2C9 activity humans unknown. This study evaluated effects nilotinib pharmacokinetics pharmacodynamics warfarin, sensitive substrate, healthy subjects.
springer.com
sci-hub.se 参考文章(22)
A. Breckenridge, M. Orme, H. Wesseling, R. J. Lewis, R. Gibbons, Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clinical Pharmacology & Therapeutics. ,vol. 15, pp. 424- 430 ,(1974) , 10.1002/CPT1974154424
Srdan Verstovsek, Mirna Golemovic, Hagop Kantarjian, Tashi Manshouri, Zeev Estrov, Paul Manley, Tong Sun, Ralph B Arlinghaus, Leila Alland, Margaret Dugan, Jorge Cortes, Francis Giles, Miloslav Beran, None, AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells Cancer. ,vol. 104, pp. 1230- 1236 ,(2005) , 10.1002/CNCR.21299
L.Z Benet, Relevance of pharmacokinetics in narrow therapeutic index drugs. Transplantation proceedings. ,vol. 31, pp. 1642- 1644 ,(1999) , 10.1016/S0041-1345(99)00083-4
Hiroshi Yamazaki, Tsutomu Shimada, Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R- and S-warfarin enantiomers. Biochemical Pharmacology. ,vol. 54, pp. 1195- 1203 ,(1997) , 10.1016/S0006-2952(97)00304-3
Leslie Z Benet, Betty-ann Hoener, Changes in plasma protein binding have little clinical relevance. Clinical Pharmacology & Therapeutics. ,vol. 71, pp. 115- 121 ,(2002) , 10.1067/MCP.2002.121829
H Takahashi, H Echizen, Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin Pharmacogenomics Journal. ,vol. 3, pp. 202- 214 ,(2003) , 10.1038/SJ.TPJ.6500182
Hagop Kantarjian, Francis Giles, Lydia Wunderle, Kapil Bhalla, Susan O'Brien, Barbara Wassmann, Chiaki Tanaka, Paul Manley, Patricia Rae, William Mietlowski, Kathy Bochinski, Andreas Hochhaus, James D. Griffin, Dieter Hoelzer, Maher Albitar, Margaret Dugan, Jorge Cortes, Leila Alland, Oliver G. Ottmann, Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL The New England Journal of Medicine. ,vol. 354, pp. 2542- 2551 ,(2006) , 10.1056/NEJMOA055104
Laurence S. Kaminsky, Zhi-Yi Zhang, Human P450 metabolism of warfarin. Pharmacology & Therapeutics. ,vol. 73, pp. 67- 74 ,(1997) , 10.1016/S0163-7258(96)00140-4
Avraham Yacobi, Gerhard Levy, Protein binding of warfarin enantiomers in serum of humans and rats Journal of Pharmacokinetics and Biopharmaceutics. ,vol. 5, pp. 123- 131 ,(1977) , 10.1007/BF01066216
Frank J. Diana, Karen Veronich, Amrit L. Kapoor, Binding of Nonsteroidal Anti-Inflammatory Agents and Their Effect on Binding of Racemic Warfarin and Its Enantiomers to Human Serum Albumin Journal of Pharmaceutical Sciences. ,vol. 78, pp. 195- 199 ,(1989) , 10.1002/JPS.2600780304